title: Second-line treatment paradigms for diffuse large B-cell lymphomas.
abstract: Despite recent major advances in treating diffuse large B-cell lymphoma with dose-intense regimens and the addition of the anti-CD20 monoclonal antibody rituximab, a significant proportion of patients will experience early treatment failure, partial response, or relapse after initial chemotherapy. For more than 10 years, the standard treatment for chemosensitive relapses has been based on salvage chemotherapy followed by high-dose therapy and autologous stem cell transplantation in selected patients. However, several important questions remain: What is the best salvage regimen? What is the efficacy of rituximab in an era when R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is accepted as standard care for frontline therapy? What are the risk factors in second-line therapy? What is the best treatment when high-dose therapy and autologous stem cell transplantation are not possible? This article reviews all these issues and discusses new biologic therapies, with the knowledge that improvements in outcome may be achieved through a greater understanding of the biologic parameters associated with poorer prognosis.
authors.affiliation: Hôpital Saint Louis, Hemato-Oncologie, Institut Universitaire d'Hématologie, 1 Avenue Claude Vellefaux, 75010 Paris, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Thieblemont
authors.forename: Christian
authors.initials: C
authors.lastname: Gisselbrecht
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D003520:Cyclophosphamide; D004317:Doxorubicin; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology; D011241:Prednisone; D000069283:Rituximab; D016879:Salvage Therapy / Q000379:methods*; D016019:Survival Analysis; D014750:Vincristine
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
references.citation: Cancer Biother Radiopharm. 2007 Feb;22(1):113-20
references.pmid: 17627419
references.citation: Oncology. 2005;69(6):499-502
references.pmid: 16424679
references.citation: Haematologica. 2006 Jan;91(1):114-20
references.pmid: 16434379
references.citation: J Clin Oncol. 2005 Jun 20;23(18):4117-26
references.pmid: 15867204
references.citation: Bone Marrow Transplant. 2007 Dec;40(11):1007-17
references.pmid: 17922042
references.citation: Exp Hematol. 2007 Apr;35(4):534-40
references.pmid: 17379063
references.citation: Ann Oncol. 2006 May;17 Suppl 4:iv31-2
references.pmid: 16702182
references.citation: N Engl J Med. 1995 Dec 7;333(23):1540-5
references.pmid: 7477169
references.citation: Leuk Lymphoma. 2007 Apr;48(4):708-15
references.pmid: 17454628
references.citation: Leuk Lymphoma. 2006 Dec;47(12):2558-66
references.pmid: 17169800
references.citation: Haematologica. 2008 Dec;93(12):1829-36
references.pmid: 18945747
references.citation: Cancer Sci. 2006 Sep;97(9):933-7
references.pmid: 16805825
references.citation: Blood. 2004 May 15;103(10):3684-8
references.pmid: 14739217
references.citation: J Med Chem. 2008 Nov 13;51(21):6902-15
references.pmid: 18841882
references.citation: Leuk Lymphoma. 2005 Jan;46(1):71-5
references.pmid: 15621783
references.citation: Blood. 1998 Nov 15;92(10):3562-8
references.pmid: 9808548
references.citation: Ann Oncol. 2007 Aug;18(8):1363-8
references.pmid: 17496309
references.citation: J Clin Oncol. 2007 May 1;25(13):1741-6
references.pmid: 17389337
references.citation: Nat Rev Cancer. 2005 Apr;5(4):275-84
references.pmid: 15803154
references.citation: Blood. 2004 Feb 1;103(3):777-83
references.pmid: 12907446
references.citation: Blood. 2008 Feb 15;111(4):2230-7
references.pmid: 18006696
references.citation: Ann Hematol. 2007 Apr;86(4):271-6
references.pmid: 17216473
references.citation: Br J Haematol. 2001 Dec;115(4):786-92
references.pmid: 11843810
references.citation: Am J Hematol. 2009 Feb;84(2):93-7
references.pmid: 19123458
references.citation: Blood. 2004 Aug 1;104(3):634-41
references.pmid: 15016643
references.citation: Cancer Chemother Pharmacol. 2009 Oct;64(5):907-16
references.pmid: 19219604
references.citation: J Clin Oncol. 2008 Jan 1;26(1):90-5
references.pmid: 18025438
references.citation: Ann Oncol. 2006 May;17 Suppl 4:iv18-24
references.pmid: 16702180
references.citation: J Clin Oncol. 2006 Aug 20;24(24):3880-6
references.pmid: 16864854
references.citation: N Engl J Med. 2002 Jan 24;346(4):235-42
references.pmid: 11807147
references.citation: Eur J Haematol. 2008 Feb;80(2):127-32
references.pmid: 18005385
references.citation: J Clin Oncol. 1992 Oct;10(10):1615-23
references.pmid: 1383435
references.citation: Oncol Rep. 2003 Nov-Dec;10(6):1915-7
references.pmid: 14534718
references.citation: J Clin Oncol. 1998 Oct;16(10):3264-9
references.pmid: 9779700
references.citation: Blood. 2008 Jan 15;111(2):537-43
references.pmid: 17971487
references.citation: J Clin Oncol. 2005 Apr 1;23(10):2240-7
references.pmid: 15800314